ATE210727T1 - Abgeschwächtes impf- und gentransferase-virus, verfahren zu dessen herstellung und arzneimittel, das es enthält - Google Patents

Abgeschwächtes impf- und gentransferase-virus, verfahren zu dessen herstellung und arzneimittel, das es enthält

Info

Publication number
ATE210727T1
ATE210727T1 AT95933386T AT95933386T ATE210727T1 AT E210727 T1 ATE210727 T1 AT E210727T1 AT 95933386 T AT95933386 T AT 95933386T AT 95933386 T AT95933386 T AT 95933386T AT E210727 T1 ATE210727 T1 AT E210727T1
Authority
AT
Austria
Prior art keywords
virus
vrna
viral
promoter
progeny
Prior art date
Application number
AT95933386T
Other languages
English (en)
Inventor
Gerd Hobom
Gabriele Neumann
Annette Menke
Original Assignee
Hobom Gerd Prof Dr Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hobom Gerd Prof Dr Dr filed Critical Hobom Gerd Prof Dr Dr
Application granted granted Critical
Publication of ATE210727T1 publication Critical patent/ATE210727T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95933386T 1994-09-30 1995-09-18 Abgeschwächtes impf- und gentransferase-virus, verfahren zu dessen herstellung und arzneimittel, das es enthält ATE210727T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94115505A EP0704533A1 (de) 1994-09-30 1994-09-30 Abgeschwächtes Impfvirus, Verfahren zur dessen Herstellung und Arzneimittel die es enthalten
PCT/EP1995/003663 WO1996010641A1 (en) 1994-09-30 1995-09-18 An attenuated vaccination and gene-transfer virus, a method to make the virus and a pharmaceutical composition comprising the virus

Publications (1)

Publication Number Publication Date
ATE210727T1 true ATE210727T1 (de) 2001-12-15

Family

ID=8216345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933386T ATE210727T1 (de) 1994-09-30 1995-09-18 Abgeschwächtes impf- und gentransferase-virus, verfahren zu dessen herstellung und arzneimittel, das es enthält

Country Status (10)

Country Link
US (1) US6524588B1 (de)
EP (3) EP0704533A1 (de)
JP (1) JP2000509962A (de)
AT (1) ATE210727T1 (de)
AU (1) AU3607695A (de)
DE (1) DE69524618T2 (de)
ES (1) ES2165434T3 (de)
FI (1) FI971272A7 (de)
NZ (1) NZ293600A (de)
WO (1) WO1996010641A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809666D0 (en) * 1998-05-06 1998-07-01 Isis Innovation Modified viruses
EP1035209A1 (de) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stabile rekombinante Influenzaviren, die frei von Helfervirus sind
EP1185615B1 (de) * 1999-04-06 2007-08-01 Wisconsin Alumni Research Foundation Rekombinante influenzaviren zur vakzinherstellung und gentherapie
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1201760A1 (de) * 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza Virus Vektor für humane dentritische Zellen
US20030099670A1 (en) * 2001-02-09 2003-05-29 Gert Hobom Influenza viruses with enhanced transcriptional and replicational capacities
EP1814990A2 (de) 2004-11-19 2007-08-08 Wisconsin Alumni Research Foundation Rekombinante influenza-vektoren mit transkriptionseinheiten, die in tandem vorliegen
WO2007133682A2 (en) * 2006-05-11 2007-11-22 Geneohm Sciences, Inc. 100% sequence identity detection methods for variable genomes
TWI386176B (zh) * 2008-02-08 2013-02-21 Colgate Palmolive Co 口腔保健牙刷
RU2519329C2 (ru) * 2008-02-08 2014-06-10 Колгейт-Палмолив Компани Композиции и устройства
RU2493812C2 (ru) * 2008-02-08 2013-09-27 Колгейт-Палмолив Компани Зубной герметик
CA2706516C (en) * 2008-02-08 2014-12-16 Colgate-Palmolive Company Cleaning compositions and methods
WO2009100279A2 (en) * 2008-02-08 2009-08-13 Colgate-Palmolive Company Compositions comprising basic amino acid and soluble carbonate salt
WO2009100276A2 (en) 2008-02-08 2009-08-13 Colgate-Palmolive Company Dental floss
RU2460510C2 (ru) * 2008-02-08 2012-09-10 Колгейт-Палмолив Компани Шипучие композиции
CN101938990A (zh) * 2008-02-08 2011-01-05 高露洁-棕榄公司 包含碱性氨基酸肽和蛋白酶的组合物和方法
EP3943064A1 (de) * 2008-02-08 2022-01-26 Colgate-Palmolive Company Mundpflegeprodukt und anwendungs- und herstellungsverfahren dafür
JP2011511793A (ja) * 2008-02-08 2011-04-14 コルゲート・パーモリブ・カンパニー 口内乾燥の処置のための組成物および方法
EP2249791A4 (de) 2008-02-08 2014-01-08 Colgate Palmolive Co Zusammensetzungen und vorrichtungen
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
US9315464B1 (en) 2013-01-31 2016-04-19 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104593330A (zh) * 2015-01-19 2015-05-06 中国科学院微生物研究所 含有a型流感特异性启动子的重组293t细胞及其应用
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (de) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vektoren zur auslösung von immunantworten auf nicht-dominante epitope im hämagglutinin (ha)-protein
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
EP4093415A1 (de) 2020-01-24 2022-11-30 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenza-viren mit stabilisiertem na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5690937A (en) * 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene

Also Published As

Publication number Publication date
DE69524618T2 (de) 2002-08-14
FI971272A0 (fi) 1997-03-26
EP0783586A1 (de) 1997-07-16
NZ293600A (en) 1999-01-28
US6524588B1 (en) 2003-02-25
EP0704533A1 (de) 1996-04-03
AU3607695A (en) 1996-04-26
WO1996010641A1 (en) 1996-04-11
JP2000509962A (ja) 2000-08-08
EP1091000A1 (de) 2001-04-11
FI971272A7 (fi) 1997-05-26
DE69524618D1 (de) 2002-01-24
ES2165434T3 (es) 2002-03-16
EP0783586B1 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
DE69524618D1 (de) Abgeschwächtes impf- und gentransferase-virus, verfahren zu dessen herstellung und arzneimittel, das es enthält
Berkner et al. Generation of adenovirus by transfection of plasmids
EP1035209A1 (de) Stabile rekombinante Influenzaviren, die frei von Helfervirus sind
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
CA2406100A1 (en) Dna transfection system for the generation of infectious influenza virus
HUP9900050A1 (hu) Rekombináns adenovírusok, és felhasználásuk adeno-asszociált vírusok (AAV) előállítására, komplementáló sejtvonalak, és az illető adenovírusokat tartalmazó gyógyszerkészítmények
Le Nouën et al. Attenuation of human respiratory viruses by synonymous genome recoding
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
JP2002536978A5 (de)
MXPA02005525A (es) Clones infecciosos.
JPH06343477A (ja) 医薬的および診断的使用のための組み換えフオーミーウイルスベクター、および組み換えフオーミーウイルスベクターの作製方法
CN103215308A (zh) 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
Bergmann et al. Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation
CN119256086A (zh) 工程化基因效应因子、组合物及其使用方法
SK137797A3 (en) Recombinant viral vector, pharmaceutical composition containing the same and corresponding transformed cells
ATE100495T1 (de) Rekombinantes marek-krankheitsvirus, verfahren zu seiner herstellung, und vakzine.
US6514757B1 (en) Nodavirus-like DNA expression vector and uses thereof
Atwater et al. Biosynthesis of reovirus-specified polypeptides Efficiency of expression of cDNAs of the reovirus S1 and S4 genes in transfected animal cells differs at the level of translation
US7034142B1 (en) Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins
Fukazawa et al. Complete nucleotide sequence of the gene encoding the rat apolipoprotein E
US20030008277A1 (en) Recombinant segmented negative strand virus containing bicistronic vRNA segment with a duplication of its 3' noncoding flanking sequence, and vaccines and therapeutic compositions containing the same
EP1174514A1 (de) Rekombinante Influenza -Viren mit für zwei in Tandemordnung Genen kodierenden bicistronischen vRNS
Vogel et al. Overlapping palindromic sequences associated with somatic deletion and meiotic recombination of MHC class I genes
Riedl Advancing viral vector technologies overcoming challenges in large DNA virus manipulation and introducing novel platforms for gene delivery

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee